International Isotopes Inc., now operating under the name Radnostix Inc., reported a total revenue of approximately $13.07 million for the fiscal year ending December 31, 2025, marking a 6% decrease from the previous year's revenue of $13.90 million. The company experienced a net loss of $908,002, a significant decline from a net income of $8,574 in 2024. The decrease in revenue was attributed to lower sales in the Theranostics and Cobalt Products segments, which saw declines of 15% and 26%, respectively, due to raw material supply issues and operational shutdowns for refurbishments.
In contrast, the Calibration & Reference Products segment reported a 21% increase in sales, reaching $4.25 million, driven by the recovery from previous supply shortages and the introduction of new products. The Medical Devices segment, which began operations in 2024, generated $229,000 in revenue, reflecting a substantial increase from the prior year. The company’s gross profit margin decreased to 59% from 62% in 2024, primarily due to changes in the sales mix and increased costs associated with raw materials.
Strategically, Radnostix has focused on expanding its product offerings and market presence. The company is set to launch the EasyFill Automated Capsule System in the third quarter of 2026, aimed at enhancing its Theranostics Products segment. Additionally, the company has made significant investments in its Calibration & Reference Products facility, which is expected to improve manufacturing capacity and product quality. The termination of an asset purchase agreement with American Fuel Resources for the Fluorine Products segment allows Radnostix to retain control over its assets, which the company believes have appreciated in value.
Operationally, Radnostix employed 45 individuals as of December 31, 2025, and has been actively working to mitigate supply chain risks, particularly concerning critical isotopes like cobalt-60 and gadolinium-153. The company has established new supplier relationships to ensure a steady flow of materials and is exploring additional markets for its products. Looking ahead, Radnostix aims to achieve profitability by expanding its customer base, increasing revenues, and reducing production costs, while also evaluating potential acquisitions to enhance its product offerings.
Overall, while Radnostix faced challenges in 2025, including supply chain disruptions and a decline in certain product revenues, the company is positioning itself for future growth through strategic investments and product development initiatives. The outlook for 2026 includes plans to expand sales of its FDA-approved sodium iodide I-131 product and to complete the development of new medical devices, which are expected to contribute positively to the company's financial performance.
About INTERNATIONAL ISOTOPES INC
International Isotopes Inc. produces and distributes nuclear medicine radiopharmaceuticals, calibration standards, and cobalt-60 products for medical, industrial, and research markets. The company offers FDA-approved radiopharmaceuticals, develops medical devices, and operates in regulated environments with a focus on safety and compliance. Its core business includes manufacturing, product development, and strategic partnerships in global markets, emphasizing innovation, regulatory adherence, and expanding market share in isotope applications.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.